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Abstract
Context: From one country to another, the pay-for-performance mechanisms differ on one significant point: the
identification of target populations, that is, populations which serve as a basis for calculating the indicators. The aim of this
study was to compare clinical versus medication-based identification of populations of patients with diabetes and
hypertension over the age of 50 (for men) or 60 (for women), and any consequences this may have on the calculation of P4P
indicators.
Methods: A comparative, retrospective, observational study was carried out with clinical and prescription data from a panel
of general practitioners (GPs), the Observatory of General Medicine (OMG) for the year 2007. Two indicators regarding the
prescription for statins and aspirin in these populations were calculated.
Results: We analyzed data from 21.690 patients collected by 61 GPs via electronic medical files. Following the clinical-based
approach, 2.278 patients were diabetic, 8,271 had hypertension and 1.539 had both against respectively 1.730, 8.511 and
1.304 following the medication-based approach (% agreement=96%, kappa=0.69). The main reasons for these differences
were: forgetting to code the morbidities in the clinical approach, not taking into account the population of patients who
were given life style and diet rules only or taking into account patients for whom morbidities other than hypertension could
justify the use of antihypertensive drugs in the medication-based approach. The mean (confidence interval) per doctor was
33.7% (31.5–35.9) for statin indicator and 38.4% (35.4–41.4) for aspirin indicator when the target populations were identified
on the basis of clinical criteria whereas they were 37.9% (36.3–39.4) and 43.8% (41.4–46.3) on the basis of treatment criteria.
Conclusion: The two approaches yield very ‘‘similar’’ scores but these scores cover different realities and offer food for
thought on the possible usage of these indicators in the framework of P4P programmes.
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Introduction
Over the past few years a set of indicators has been developed to
measure the quality of healthcare in the framework of pay for
performance (P4P) programmes [1,2]. The underlying principle is
that health practitioners are rewarded for the achievement of
certain quality standards in their healthcare delivery, measured
against a set of specific indicators. The logic derives from standard
economic theory which holds that appropriate external incentives
(here, financial) are likely to alter individuals’ behaviour and steer
it in the required direction [3]. This new mode of remuneration
has targeted primary care and especially general practice [4].To
date, the most conclusive experiment in this respect has been in
the UK where P4P has been implemented since April 2004 with a
set of indicators developed in the Quality and Outcomes
Framework [5,6]. Other countries such as the US, Australia,
New Zealand and Israel have also adopted this mode of payment
[7,8]. In France the introduction of a system based on a similar
principle was proposed in 2009 by the national health insurance
fund for employees (Caisse Nationale d’Assurance Maladie des
Travailleurs Salarie ´s (CNAMTS)) [9], under its P4P programme
called Contract for Enhancing the Individual Practices (Contrats
d’Ame ´lioration des Pratiques Individuelles (CAPI)). This programme is
based on a set of 16 indicators. Nine of them have healthcare
objectives and are divided into two categories. The first,
‘‘screening and prevention’’, concerns for example the percentage
of a doctor’s patients in the 50–74 age-group who have had breast-
cancer screening, or the rate of flue vaccination among patients
over 65. The second, ‘‘treatment of chronic pathologies’’,
primarily concerns adherence to recommendations concerning
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heading ‘‘optimization of prescriptions’’, aim at rationalizing
healthcare and encouraging the prescription of generic medicines.
From one country to another, the P4P mechanisms differ on
one significant point: the identification of target populations, that
is, populations which serve as a basis for calculating the indicators.
In the UK, target populations are identified on the basis of clinical
data collected by practitioners in a standardized way during
consultations. For this purpose doctors use medical software
meeting compatibility standards and enabling them to transfer
their data. This mode of identification is criticized in certain
respects, mainly because it allows for misreporting when doctors
code data [10,11], and because the time taken to code data may
reduce the time spent listening to the patient [12]. In France, the
identification of target populations is based on the medication
prescribed by doctors and reimbursed by the compulsory health
insurance fund. These data are drawn from the health insurance
fund’s database which routinely collects information from all
patients affiliated with this fund for the reimbursement of their
health care. This mode of identification based on reimbursed
medication does not require doctors to code data. But already the
limits of this mode of identification based on medication have
emerged. This is for example because the same medicine may
have several indications [13]. To our knowledge, no comparative
research of these two modes of identification or of their
consequences on the calculation of indicators has been yet
undertaken.
We considered it interesting to study these two approaches,
drawing on an original database containing both the diagnoses
and the prescribed treatments of over 80,000 patients. This
database is fed by data collected routinely by a network of
volunteer GPs [14]. To this end we chose a target population
whose care is subject to good practice recommendations, that is,
patients with three cardio-vascular risk factors: age, hypertension
and diabetes.
The aim of this study was to compare clinical versus medication
- based identification of populations of patients with diabetes and
hypertension over the age of 50 (for men) or 60 (for women), and
any consequences this may have on the calculation of P4P
indicators.
Materials and Methods
We carried out a comparative, retrospective, observational
study.
General practitioner sampling
Data on patients, diseases and related health problems were
drawn from French GPs’ electronic medical records. These were
accessed via the database which the French Society of General
Practice (Socie ´te ´ Franc ¸aise de Me ´decine Ge ´ne ´rale (SFMG)) has been
compiling since 1993 in a network of 90 GPs working mainly in
solo practices (SFMG-DB). The participants in this network
routinely register data in their daily practice. They are largely
representative of the French GP population, although a compar-
ison with data from the Ministry of Health shows that doctors
working in rural areas were under-represented [15,16]. We studied
the practices of the 61 GPs for whom complete information with
regard to diseases and related health problems or prescriptions
were available during 2007 i.e. just before the implementation of
the CAPI.
Patient registration
The 61 GPs had cared for a total of 81,052 patients whose age
and sex distribution did not differ significantly from that of the
population as a whole. For the present data-based study, we only
selected patients older than 50 for men and 60 for women, that is,
populations which served as a basis for calculating the indicators
(see below), which gave us a sample of 21,690 patients.
Identification using clinical codes
In the SFMG-DB, diseases and related health problems are
coded using the Dictionary of Consultation Results (DCR), which
has been validated in France [17]. The corresponding codes in the
International Classification of Diseases, 10th Revision, Clinical
Modifications (ICD-10-CM) are also mentioned. The diseases and
related health problems of interest in our study were type 2
diabetes (CR 818/ICD E11) and hypertension (CR 826/ICD I10).
Identification using medications
In the SFMG-DB, medications are coded according to the
Anatomical Therapeutic Chemical (ATC) Classification System
(WHO, 2006). We retained two therapeutic categories for
diabetes: (i) Insulin: ATC group A10A, and (ii) oral anti-diabetic
medics: ATC group A10B and C10A. Five therapeutic categories
were retained for hypertension: (i) Adrenergic beta-antagonists:
ATC group C07, (ii) diuretics: ATC groupC03, (iii) Calcium
channel blockers: ATC group C08, (iv) Angiotensin-converting
enzyme inhibitors: ATC group C09A and Angiotensin II Type 1
Receptor Blockers: ATC group C09C, (v) other antihypertensive
agents: ATC group C02 (Table 1). ATC codes for acetyl salicylic
acid and statins were respectively B01AC06, N02BA01 and
C10AA01–C10AA08.
Constitution of target populations according to the two
modes of identification
With the medication approach, we first identified two
populations within the set of patients over the age of 50 (men)
or 60 (women): the ‘‘Medication Identified Diabetes’’ and the
‘‘Medication Identified Hypertension’’ populations. They were
constituted only on the basis of the medication prescribed. To be
included in the population, a patient had to have received, in the
year 2007, at least one prescription for a diabetes treatment (oral
or insulin), for the ‘‘Medication Identified Diabetes’’, and at least
one prescription for a hypertension treatment, for the ‘‘Medication
Identified Hypertension’’ population. Finally, by cross-comparing
the two populations it was possible to obtain the ‘‘Medication
Identified Diabetes and Hypertension’’ population corresponding
to our target population identified on the basis of treatment.
With the clinical approach, we identified the ‘‘Diagnostic Code
Identified Diabetes’’ population and the ‘‘Diagnostic Code
Identified Hypertension’’ population, based exclusively on clinical
data. To be included in the ‘‘Diagnostic Code Identified
Diabetes’’population, a patient had to have in his/her file, for
the year 2007, at least one type-2 diabetes CR, and to be included
in the ‘‘Diagnostic Code Identified Hypertension’’ population, at
least one hypertension CR. The cross-comparison of the two
populations enabled us to obtain the ‘‘Diagnostic Code Identified
Diabetes and Hypertension’’ population, that is, our target
population identified on the basis of clinical data.
Analysis of data concordance
We calculated % agreement, and Kappa scores to analyse data
concordance between the two approaches.
Two Approaches to Calculate Performance Scores
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Two indicators defined following the guidelines developed by
the ‘‘Haute Autorite ´ de Sante ´’’ [18] were then calculated
according to the two modes of identification:
Statin Indicator=patients (age.50 for men and .60 for
women) with diabetes and hypertension, taking statin/patients
(age.50 for men and .60 for women) with diabetes and
hypertension. For information, the target objective for this
indicator in the CAPI framework is 75%.
Aspirin Indicator=patients (age.50 for men and .60 for
women) with diabetes and hypertension, taking statin and aspirin/
patients (age.50 for men and .60 for women) with diabetes and
hypertension taking statin. The target objective for this indicator in
the CAPI framework is 65%.
The indicators were calculated individually for the 61 GPs. The
results were expressed as mean (IC at 95%).
Ethics committee
We did not seek ethical approval for this study because in
France, there was no need for an ethics committee approval as the
data used in this study were collected as part of routine medical
practice and also because there was no supplementary data
collected and no specific intervention on the patient. However, it
should be mentioned that patients all gave their informed consent
for the anonymous registration of their clinical data in the SFMG-
DB and also for the use of these data for research and this was
approved by the Commission Nationale de l’Informatique et des
Liberte ´s (CNIL) (approval nu 311668).
Results
Target population of diabetic patients according to the
two modes of identification
Among 21,690 patients in our sample, 19,412 did not have a
diagnostic code for diabetes, whereas 2,278 did; in contrast,
19,960 did not receive a medication for diabetes, whereas 1,730
did (% agreement=96%, kappa=0.78) (Table 2). The 666
patients clinically coded as being diabetic but who received no
medication for diabetes can be considered as diabetic patients
treated exclusively with rules pertaining to life style and diet. This
represented 27.8% (666/(1,730+666) of the patients with diabetes
in our sample. It should be noted that as treatment data are taken
directly from the prescriptions drawn up on computer and
delivered to patients, theoretically the doctor could not have
forgotten to enter the ATC code. The 118 patients who received a
treatment for diabetes without the diabetes CR code being
recorded correspond to cases where the code was forgotten,
because these were medications which had no indication other
than diabetes, except for metformine which is occasionally used to
treat polycystic ovarian syndrome but this did not concern any of
our patients. The rate of forgetting the code in the clinical
approach was 4.9% (118/(2,278+118)).
Target population of patients with hypertension
according to the two modes of identification
Among 21,690 patients in our sample, 13,419 did not have a
diagnostic code for hypertension, whereas 8,271 did; in contrast,
13,179 did not receive a medication for hypertension, whereas
8,511 did (% agreement=84%, kappa=0.67) (Table 3). The
1,592 patients with the hypertension CR code being recorded but
without a treatment for hypertension can be considered as patients
with untreated hypertension, either deliberately because they were
following life style and diet rules, or because of delays in starting
the treatment. This represented 15.8% (1,592/(8,511+1,592)) of
the patients with hypertension in our sample. Some but not all of
the 1,832 patients who received a treatment indicated for
hypertension, without having the hypertension CR code being
recorded, were cases where the code was forgotten. There were
also patients for whom morbidity other than hypertension could
Table 1. ATC codes for prescription data.
Indication Classe ATC Molecules
Diabe `te A10A human insulin, bovine insulin, pig insulin, insulin asparte, insulin glulisine
A10B metformin, glibenclamide, chlorpropamide, tolbutamine, glibornuride, carbutamide, glipizide, gliclazide,
glimepiride, acarbose, miglitol, rosiglitazone, pioglitazone, sitagliptine, repaglinide, exanatide
C10A benflorex
Hypertension C02 reserpine, methyldopa, clonidine, guanfacine, tolonidine, moxonidine, rilmenidine, prazosine, urapidil,
dihydralazine, minoxidil
C03 bendroflumethiazide, hydroflumethiazide, hydrochlorothiazide, polythiazide, methyclothiazide, clopamide,
chlortalidone, xipamide, indapamide, cicletanine, furosemide, piretanide, tienilique acide, spironolactone,
canrenone, amiloride, triamterene
C07 oxprenolol, pindolol, propranolol, timolol, nadolol, carteolol, tertatolol, penbutolol, metoprolol, atenolol,
acebutolol, betaxolol, bisoprolol, celiprolol, nebivolol, labetalol
C08 amlodipine, felodipine, isradipine, nicardipine, nifedipine, nitrendipine, lacidipine, manidipine, lercanidipine,
mibefradil, verapamil, diltiazem
C09A captopril, enalapril, lisinopril, perindopril, ramipril, quinapril, benazepril, cilazapril, fosinopril, trandolapril,
moexipril, zofenopril, imidapril
doi:10.1371/journal.pone.0035721.t001
Table 2. Target population of diabetic patients according to
the two modes of identification.
Medication-based identification
Clinical-based identification NO YES TOTAL
NO 19,294 118 19,412
YES 666 1,612 2,278
TOTAL 19,960 1,730 21,690
doi:10.1371/journal.pone.0035721.t002
Two Approaches to Calculate Performance Scores
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not only for hypertension but also for another indication.
Therefore, these patients did not correspond to cases where the
code was forgotten since they did not have hypertension. This
concerned 1088 patients, i.e. 12.8% of the population with
medications for hypertension (1088/8511), who had at least one
morbidity among the following which required a medication of
this type (angina pectoris (CR 711/ICD I20.9), heart failure (CR
820/ICD I50.9), atrial fibrillation (CR 819/ICD I48), other
cardiac arrhythmias (CR 823/ICD R00.8), isolated leg oedema
(CR 223/ICD R60.0), kidney failure (CR 179/ICD N19),
migraine disorders (CR 206/ICD G43.9), cirrhosis (CR 838/
ICD K74.6), tremor (CR 296/ICD R25.1), hyperthyroidism (CR
604/ICD E05.9), Raynaud’s syndrome (CR 7/ICD I73.0) and/or
benign prostatic hyperplasia (CR 845/ICD N40)). The remaining
744 could be considered as actually having hypertension and
corresponding to a case where the hypertension CR code was
forgotten. The rate of forgetting the code in the clinical approach
was 8.2% (744/8,271+744)).
Target population of patients with diabetes and
hypertension according to the two modes of
identification
Among 21,690 patients in our sample, 20,151 did not have a
diagnostic code for diabetes and hypertension, whereas 1,539 did;
in contrast, 20,386 did not receive a medication for diabetes and
hypertension, whereas 1,304 did (% agreement=96%, kap-
pa=0.69) (Table 4). The clinical approach enabled us to identify
531 patients with hypertension and diabetes, not identified by the
medication-based method. Conversely, identification on the basis
of medications enabled us to identify 296 patients not identified on
the basis of clinical criteria. Yet by using the same reasoning as
above, 112 of the latter patients must be considered as not having
hypertension even though they received treatment for hyperten-
sion. Thus, a total of 184 patients were identified as having
diabetes and hypertension, based on their medications but not on
clinical criteria.
Calculation of the P4P indicators
The mean per doctor of statin indicator when the target
populations were identified on the basis of clinical criteria was
33.7% (31.5–35.9) whereas it was 37.9% (36.3–39.4) when the
target populations were identified on the basis of treatment
criteria.
For aspirin indicator, the mean per doctor was 38.4% (35.4–
41.4) after clinical identification and 43.8% (41.4–46.3) after
medication identification.
Two physicians moved from above to below the expected rates
of 65% for the statin indicator when switching from the
medication identification to the diagnostic identification. None
of them did in the other way. Three physicians moved from above
to below the expected rates of 75% for the aspirin indicator when
switching from the medication identification to the diagnostic
identification, one moved in the other way. (Figures 1 and 2)
Discussion
The aim of this article was to compare clinical versus
medication - based identification of populations of patients with
diabetes and hypertension and the effects each of them could have
on the calculation of P4P indicators. We showed that there was a
quite good degree of data concordance and that the results of the
P4P indicators obtained with the two methods differ little in terms
of final scores (difference of 4% in favour of the medication-based
identification) but that these results correspond to different
realities.
We observed that both of these two modes of identification can
cause the target populations to be under-estimated, either – to a
small extent – due to the doctor forgetting to code the morbidities,
in the case of clinical identification, or – to a greater extent – due
to the fact that patients whose only treatment is life style and diet
rules are not taken into account in medication-based identification.
Hence, in both cases the level of the indicator can be over-
estimated. In our study, the rate of forgetting to code the
morbidities in the clinical approach is 4.9% for diabetes and 8.2%
for hypertension. These results are consistent with those already
published in the literature assessing the completeness and
correctness of computerized general practice medical records
where the rate of forgetting to code the morbidities was situated
between 5 and 10% [19,20]. Medication-based identification
under-estimates the population of diabetic patients by 27.8%
because there are patients who are given life style and diet rules
only. The percentage of such patients is higher in our sample than
it is in the French literature, where it oscillates between 10% and
15% [21–23] without any clear explanation for this. However it
goes along with the results of a cross-sectional study of 253 618
patients lead in the UK in 2004 which showed that 31.3% of all
patients with type 2 diabetes were being managed with diet only
[24]. Concerning patients with hypertension, the medication-
based identification under-estimates this population by 15.8% due
to patients following lifestyle and diet rules only, and to the well-
known therapeutic inertia in hypertension. This rate of patients
with untreated hypertension is lower than that reported in a large
country-wide study on general practice in France where one third
of the 70,000 studied had never received hypertension medication
[25]. This rate was also estimated at 27.5% in a US study [26].
The medication mode of identification can on the other hand
result in an over-estimation of the target population of patients
with hypertension, and consequently in the under-estimation of
the level of the indicator, since medications for hypertension may
be indicated to treat morbidities other than hypertension. In our
Table 3. Target population of patients with hypertension
according to the two modes of identification.
Medication-based identification
Clinical-based identification NO YES TOTAL
NO 11,587 1,832 13,419
YES 1,592 6,679 8,271
TOTAL 13,179 8,511 21,690
doi:10.1371/journal.pone.0035721.t003
Table 4. Target population of patients with diabetes and
hypertension according to the two modes of identification.
Medication-based identification
Clinical-based identification NO YES TOTAL
NO 19,855 296 20,151
YES 531 1,008 1,539
TOTAL 20,386 1,304 21,690
doi:10.1371/journal.pone.0035721.t004
Two Approaches to Calculate Performance Scores
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of medication led to the inclusion of 12.8% of patients who did not
have hypertension and should not have been included. To our
knowledge this has never been underlined before. A perverse effect
of this medication-based identification, in the framework of a P4P
programme, could be to expose these patients to the risk of being
prescribed statins by non scrupulous doctors for the sole purpose of
improving their individual scores.
From an economic point of view, if we were in the framework of
a P4P programme, the mode of identification would not
substantially change doctors’ financial remuneration. This is
because the final scores obtained look ‘‘quite similar’’ when we
compare the clinical and medication-based methods whereas they
deviate from the target objectives by over 20%. However, even if
we cannot make any statistical comparison between the results
obtained with the two methods, when we look at the confidence
intervals calculated for the two indicators selected, the medication-
based identification method appears in our sample to be more
advantageous for doctors. This is probably due to the fact that the
diabetic population treated by lifestyle and diet rules only, which is
huge in our sample, is not included in this method of calculating
the indicator.
Limits of the study
This study has several limits. 1/ For the medication-based
approach, the target populations were identified on the basis of
medications prescribed by doctors, not on the basis of refunded
medications as it would be in the case of a P4P programme.
Unfortunately we did not have access to the Health Insurance
reimbursement database. No study today enables us to assess the
extent of the gap there may be between medications prescribed
and medications bought by the patients and reimbursement by
health insurance. We can posit that it is narrow in these
populations of patients with chronic diseases who tend to be
compliant with their doctor’s prescription. 2/ We cannot conclude
on the statistical significance (or not) of the difference between the
scores according to the mode of identification, as the construction
of the indicators was based on different populations. We can only
Figure 1. Mean per doctor of statin indicator according to the two modes of identification.
doi:10.1371/journal.pone.0035721.g001
Figure 2. Mean per doctor of aspirin indicator according to the two modes of identification.
doi:10.1371/journal.pone.0035721.g002
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confidence interval is not large, especially since the number
observations (number of doctors, n=61) is not big. 3/ Data
collection for this study was carried out on a volunteer basis and
not in the framework of P4P. Judging by the British case, it is
possible that clinical under-coding exists with P4P [7]. This under-
coding would tend to reduce the difference between the two types
of identification by artificially improving the indicator calculated
on the basis of clinical identification. 4/ The correlation between
the two search modes in this sample of French practices is
strikingly good and probably reflects good use of diagnostic
computer entry in these patients who attend on a regular basis for
routine monitoring. This may not be generalizable across other
conditions.
Conclusion
Our findings do not enable us to conclude that one of the two
identification methods is better than the other. The two
approaches yield very similar scores but these scores cover
different realities and offer food for thought on the possible usage
of these indicators in the framework of P4P programmes.
Although it may seem reasonable to use these indicators in order
to compare a doctor’s activity from one year to the next regardless
of the identification mode, provided that it remains the same. On
the other hand, using the absolute value of an indicator seems
meaningless either for estimating the intrinsic quality of care
delivery, or to compare doctors between each other because it
depends, among other things, on how it was built.
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